METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastoma
Roshan Vaid,Ketan Thombare,Akram Mendez,Rebeca Burgos-Panadero,Anna Djos,Daniel Jachimowicz,Kristina Ihrmark Lundberg,Christoph Bartenhagen,Navinder Kumar,Conny Tümmler,Carina Sihlbom,Susanne Fransson,John Inge Johnsen,Per Kogner,Tommy Martinsson,Matthias Fischer,Tanmoy Mondal
DOI: https://doi.org/10.1093/nar/gkad1242
IF: 14.9
2024-01-06
Nucleic Acids Research
Abstract:Telomerase-negative tumors maintain telomere length by alternative lengthening of telomeres (ALT), but the underlying mechanism behind ALT remains poorly understood. A proportion of aggressive neuroblastoma (NB), particularly relapsed tumors, are positive for ALT (ALT+), suggesting that a better dissection of the ALT mechanism could lead to novel therapeutic opportunities. TERRA, a long non-coding RNA (lncRNA) derived from telomere ends, localizes to telomeres in a R-loop-dependent manner and plays a crucial role in telomere maintenance. Here we present evidence that RNA modification at the N 6 position of internal adenosine (m 6 A) in TERRA by the methyltransferase METTL3 is essential for telomere maintenance in ALT+ cells, and the loss of TERRA m 6 A/METTL3 results in telomere damage. We observed that m 6 A modification is abundant in R-loop enriched TERRA, and the m 6 A-mediated recruitment of hnRNPA2B1 to TERRA is critical for R-loop formation. Our findings suggest that m 6 A drives telomere targeting of TERRA via R-loops, and this m 6 A-mediated R-loop formation could be a widespread mechanism employed by other chromatin-interacting lncRNAs. Furthermore, treatment of ALT+ NB cells with a METTL3 inhibitor resulted in compromised telomere targeting of TERRA and accumulation of DNA damage at telomeres, indicating that METTL3 inhibition may represent a therapeutic approach for ALT+ NB.
biochemistry & molecular biology